The Zhitong Finance App learned that the quarterly revenue and adjusted earnings announced by BIIB.US (BIIB.US) exceeded analysts' expectations. This was due to increased sales of newly purchased kidney and eye disease drugs, which successfully compensated for the impact of the decline in revenue for multiple sclerosis (MS) drugs. The fiscal year showed that the company's second-quarter revenue rose 3.8% year over year to $2.7 billion, exceeding expectations of $240 million; earnings per share were $3.60, beating expectations of $1.57.

The Zhitong Finance App learned that the quarterly revenue and adjusted earnings announced by BIIB.US (BIIB.US) exceeded analysts' expectations. This was due to increased sales of newly purchased kidney and eye disease drugs, which successfully compensated for the impact of the decline in revenue for multiple sclerosis (MS) drugs. The fiscal year showed that the company's second-quarter revenue rose 3.8% year over year to $2.7 billion, exceeding expectations of $240 million; earnings per share were $3.60, beating expectations of $1.57.